Journal
Journal of Thoracic Oncology
Publication Date
6-1-2025
Volume
20
Issue
6
First Page
799
Last Page
808
Document Type
Open Access Publication
DOI
10.1016/j.jtho.2024.12.028
Rights and Permissions
Dowlati A, Chiang AC, Cervantes A, Babu S, Hamilton E, Wong SF, Tazbirkova A, Sullivan IG, van Marcke C, Italiano A, Patel J, Mekan S, Wu T, Waqar SN. Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage SCLC: Results From TROPiCS-03. J Thorac Oncol. 2025 Jun;20(6):799-808. doi: 10.1016/j.jtho.2024.12.028. Copyright 2025 International Association for the Study of Lung Cancer. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Recommended Citation
Dowlati, Afshin; Chiang, Anne C; Cervantes, Andrés; Babu, Sunil; Hamilton, Erika; Wong, Shu Fen; Tazbirkova, Andrea; Sullivan, Ivana Gabriela; van Marcke, Cédric; Italiano, Antoine; Patel, Jilpa; Mekan, Sabeen; Wu, Tia; and Waqar, Saiama N, "Phase 2 open-label study of sacituzumab govitecan as second-line therapy in patients with extensive-stage SCLC: Results from TROPiCS-03." Journal of Thoracic Oncology. 20, 6. 799 - 808. (2025).
https://digitalcommons.wustl.edu/oa_4/6144
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
